These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29660381)

  • 1. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
    Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
    Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
    Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
    Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
    Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
    Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
    Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
    Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
    Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
    Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
    Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
    Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene.
    Ma JJ; Chen BL; Xin XY
    Arch Gynecol Obstet; 2009 Feb; 279(2):149-57. PubMed ID: 18584188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.
    Kwan SY; Cheng X; Tsang YT; Choi JS; Kwan SY; Izaguirre DI; Kwan HS; Gershenson DM; Wong KK
    Oncotarget; 2016 Aug; 7(35):56933-56943. PubMed ID: 27486766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
    Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
    Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
    J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
    Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
    Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
    Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
    Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Chromatin Remodeling Component Arid1a Is a Suppressor of Spontaneous Mammary Tumors in Mice.
    Kartha N; Shen L; Maskin C; Wallace M; Schimenti JC
    Genetics; 2016 Aug; 203(4):1601-11. PubMed ID: 27280691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.